跳至主要内容
临床试验/NL-OMON44844
NL-OMON44844已完成不适用

Immunological phenotype of asthma severity (iPhase) - iPhase

Erasmus MC, Universitair Medisch Centrum Rotterdam0 个研究点目标入组 100 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
100

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 至 99(—)

入选标准

  • In order to be eligible to participate in this study, a subject must meet one of the following criteria:
  • - Diagnosis of asthma confirmed by at least one of the following as assessed at least once during the 5 past years before the study:
  • - 1. Reversibility to β2-agonists as shown by an increase from baseline in FEV1>= 12% predicted and >= 200 ml after 400 µg inhaled salbutamol or equivalent;
  • - 2. Bronchial hyper-responsiveness (BHR) to metacholine (PD < 1.76) or histamine (PD < 2.59) as measured by standardized methods.
  • - 3. Peak-flow variability of >20% ((PEFmax - PEFmin)/PEFmax) over a period of 14 days.
  • - 4. Fall in FEV1>12% and >200ml when tapering of treatment (ICS, oral steroid, LABA and/or LTRA). ;We will include patients diagnosed with asthma and a recent (< 12 monts) metacholine provocation test, or histamine provocation test (PD20 < 1.76 mg). These test are performed in a standardized manner in both centers.
  • o In this study we will compare three different asthmatic phenotypes. These phenotypes will be determined based on clinical features and inflammatory sputum profile;
  • - Use inhaled corticosteroids daily and β2-agonists as required;
  • - Given written informed consent;
  • - Age: 18 - 50.

排除标准

  • A potential subject who meets any of the following criteria will be excluded from participation in this study:;- received systemic corticosteroid therapy (>= 7.5 mg/kg) within three months prior to inclusion;
  • - no use of inhaled corticosteroids and β2-agonists
  • - BMI > 35;
  • - Smoking > 10 pack years;
  • - Other diseases which could influence pulmonary function and/or the immune system such as:
  • o A possible infection of the upper- or lower respiratory tract 4 weeks prior to the collection of materials;
  • o Chronic obstructive pulmonary disorder (COPD) in the medical history;
  • o Auto-immune diseases such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), myasthenia gravis or Goodpasture*s syndrome;
  • o Malignancies;
  • o Human immunodeficiency virus (HIV);
  • o Pregnancy;
  • o Other allergies except for allergic rhinitis.

研究者

相似试验

Immunological phenotype of asthma severity (iPhase) | 临床试验